An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer

Research output: Contribution to journalArticlepeer-review

Fingerprint Dive into the research topics of 'An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences